Abstract 1068P
Background
Several strategies based on immune checkpoint inhibitors (ICIs) have been developed or are investegated in clinical trial to assess their benefits in prolonging overall survival in cancer patients. However, ICIs-induced side effects ranging from autoimmune endocrine disorders to mucositis and to a rare but clinically significant cardiotoxicity with high rate of mortality represent important limitations. Cardiovascular complications in ICIs-treated patients includes myocarditis, vasculitis, arrhythmia, fibrosis and heart failure. Moreover, both the limited efficacy in a large portion of patients and the acquisition of resistance represent additional limitations for ICIs, underlining the need for new immunotherapy strategies. Fasting mimicking diets (FMDs) applied for several days periodically are emerging as highly promising enhancers of a wide variety of cancer therapies including immunotherapy.
Methods
A preclinical study in melanoma and lung tumor-bearing mice treated with two combinatorial ICIs therapies (anti-OX-40/PDL-1 or antiCTLA-4/anti-PD-1) during a standard or FMD was performed.
Results
FMD is highly effective in inhibiting the growth of melanoma, unlike anti-PD1/anti-CTLA4 and anti-OX40/anti-PD-L1 immunotherapy which are ineffective against both melanoma and lung cancer. However, FMD in combination with anti-OX40/anti-PD-L1 seems tofurther delay melanoma and lung cancer growth, although this trend is not statistically significant. On the other hand, cardiac fibrosis, necrosis and hypertrophy were reduced in the FMD vs standard diet group in both cancer models. Immune infiltration of CD3+ and CD8+ cells in myocardial tissues was reduced in FMD indicating myocarditis inhibition effects of the dietary intervention. Systemic and myocardial IL-1α, IL-1β, IL-6, IL17-α, G-CSF, and GM-CSF levels were also reduced in the FMD vs standard diet group.
Conclusions
These results indicate that FMD cycles applied to mouse models of melanoma and lung tumor reduce biomarkers involved in cardiovascular disease and resistance to immune-dependent activity without interfering with ICIs therapies.
Clinical trial identification
Legal entity responsible for the study
Longevity Institute and Davis School of Gerontology, University of Southern California, Los Angeles, CA, 90089, USA.
Funding
Ministero della Salute.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1333P - A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
Presenter: Min Hee Hong
Session: Poster session 19
1334P - Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency
Presenter: Alina Grecea
Session: Poster session 19
1335P - Phase Ib study to evaluate the safety and tolerability of osimertinib with ipilimumab in EGFRm NSCLC
Presenter: Sonam Puri
Session: Poster session 19
1336P - Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
Presenter: Felix Saalfeld
Session: Poster session 19
1337P - Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study
Presenter: Lin Wu
Session: Poster session 19
1338P - Cerebrospinal fluid pharmacokinetic study of lazertinib and pemetrexed in patients with EGFR-mutant non-small cell lung cancer with leptomeningeal metastases: KCSG21-01 LAZARUS trial
Presenter: Bhumsuk Keam
Session: Poster session 19
1339P - Real-world experience of dacomitinib in mEGFR Advanced NSCLC: A single centre experience
Presenter: Bivas Biswas
Session: Poster session 19
1340P - Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non–small cell lung cancer: A Chinese, multicenter, real-world cohort study
Presenter: Dongming Zhang
Session: Poster session 19
1341P - Real-world molecular testing, treatment patterns and clinical outcomes in Chinese advanced NSCLC patients, who have progressed on first-line EGFR-TKI therapy (PISCES)
Presenter: Panwen Tian
Session: Poster session 19
1342P - Effect of the timing of intervention in craniocerebral radiotherapy on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis
Presenter: Guangchuan Deng
Session: Poster session 19